SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Unity CEO Anirvan Ghosh, Ph.D./courtesy of Unity B
Drug Development
Senolytic Therapies Pose Revolutionary Potential to Roll Back Diseases of Aging
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
December 14, 2022
 · 
6 min read
 · 
Gail Dutton
Drug Development
Novel Capabilities of Innovative AntibodyPlus Therapeutics Go Beyond ADCs
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
December 13, 2022
 · 
7 min read
 · 
Gail Dutton
Employer Resources
How to Cope with Setbacks and Stay Positive in an Unpredictable Industry
Those who work in the biopharma industry often see more setbacks than successes. To understand how to overcome failures, BioSpace spoke with two experts on coping with setbacks and staying positive.
December 8, 2022
 · 
5 min read
 · 
Gail Dutton
Celmatix Founder and CEO Piraye Yurttas Beim, Ph.D
Progress Flickers in Women’s Healthcare as Femtech Builds Traction
The worldwide market for therapeutics designed specifically for conditions and diseases that affect mainly women is expected to exceed $65 billion by 2027. BioSpace looks at three femtech leaders.
December 5, 2022
 · 
7 min read
 · 
Gail Dutton
Courtesy Phunkod/Getty Images
Employer Resources
How to Enhance Your Personal Executive Brand and Expand Your Influence
Many executives haven’t established their personal brands or even know that they need one. BioSpace spoke with top executives in the field to learn about the importance of a personal executive brand.
November 28, 2022
 · 
5 min read
 · 
Gail Dutton
PepGen CFO Noel Donnelly/courtesy of PepGen
Deals
Recession Survival Strategies for Newly Public Biopharma Companies
Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.
November 24, 2022
 · 
5 min read
 · 
Gail Dutton
Jeffrey Whitford/Courtesy MilliporeSigma
Policy
Big Pharma Embraces Sustainability and Carbon Net Zero Goals
Large pharmaceutical companies are making plans to comply with sustainability and carbon net zero targets. Hear from AstraZeneca and Merck KGaA’s MilliporeSigma about their strategies.
November 18, 2022
 · 
7 min read
 · 
Gail Dutton
Illustration of ProKidney's REACT Therapy/courtesy
Drug Development
Kidney Therapeutics to Halt CKD Progression Make Late-Stage Push Toward NDA
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025.
November 18, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Beyond COVID-19 and RSV, Emerging Vaccines Target Less Common Conditions
RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.
November 15, 2022
 · 
5 min read
 · 
Gail Dutton
Stuart Peltz, Ph.D._PTC Therapeutics, Kristen Fort
Biogen, BioAge and PTC Present Novel MoAs in Neurodegenerative Diseases
BioAge Labs, PTC Therapeutics, Biogen and others highlighted novel mechanisms targeting newer pathways in neurodegenerative diseases at the recent Discovery on Target meeting.
November 4, 2022
 · 
6 min read
 · 
Gail Dutton
Phyllis Barkman Ferrell_DAC, Deanna Willis, M.D._
Drug Development
Bridging the Translational Gap between Alzheimer’s Advances and Patients
With diagnostics for Alzheimer’s already approved and therapeutics in late-stage clinical trials, the next hurdle is to translate these advances into clinical practice. The Davos Alzheimer’s Collaborative is working on it.
October 26, 2022
 · 
7 min read
 · 
Gail Dutton
Microscopic spirulina_ Lumen Bioscience, Chris Cap
Drug Development
On the Horizon, Needle-Free Vaccines could Offer Better Protection and Access
In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery, edible and intranasal vaccines.
October 25, 2022
 · 
6 min read
 · 
Gail Dutton
Rob Ross_Genevieve-de-Manio-Photography, Marc Voig
Surface, Immutep and Corbus Move Beyond Anti-PD-1/PD-LI with New Targets
PD-L1 expression is not the static, “yes/no” predictor of tumor response for which researchers hoped. Surface Oncology, Immutep and Corbus are each taking a different approach to immuno-oncology.
October 18, 2022
 · 
5 min read
 · 
Gail Dutton
FilippoBacci/Getty Images
Business
Myth Busters: Dispelling Common Myths about Heart Disease, Diabetes and Alzheimer’s
The internet and “common wisdom” aren’t always right. Here are some of the top myths about three common conditions, and the truth from leading experts in their fields.
October 12, 2022
 · 
6 min read
 · 
Gail Dutton
Roy Wu_Atom Bioscience, Dave Hava, Ph.D_Synlogic
Drug Development
New Approaches Emerge for a Prevalent Nemesis: Gout
Incidence of gout - the most common inflammatory arthritis in the world - are on the rise. Arthrosi Therapeutics, Synlogic, Atom Bioscience and Ginkgo Bioworks are on the case with novel new approaches.
October 11, 2022
 · 
5 min read
 · 
Gail Dutton
Load More